Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
30 April 2021Website:
http://www.barinthusbio.comNext earnings report:
20 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 32 min agoDividend
Analysts recommendations
Institutional Ownership
BRNS Latest News
Eight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure.
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with
OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, provided an overview of business updates and announced financial results for the third quarter of 2024. “We continue our strong execution on our clinical trials, completing enrollment in the HBV003 trial of VTP-300 in chronic hepatitis B, and advancing VTP-1000 in celiac disease into the clinic with the first in human study of the novel SNAP-TI platform,” said Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio.
In t he HBV003 trial, 67% of participants had HBsAg
What type of business is Barinthus Biotherapeutics?
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
What sector is Barinthus Biotherapeutics in?
Barinthus Biotherapeutics is in the Healthcare sector
What industry is Barinthus Biotherapeutics in?
Barinthus Biotherapeutics is in the Biotechnology industry
What country is Barinthus Biotherapeutics from?
Barinthus Biotherapeutics is headquartered in United Kingdom
When did Barinthus Biotherapeutics go public?
Barinthus Biotherapeutics initial public offering (IPO) was on 30 April 2021
What is Barinthus Biotherapeutics website?
https://www.barinthusbio.com
Is Barinthus Biotherapeutics in the S&P 500?
No, Barinthus Biotherapeutics is not included in the S&P 500 index
Is Barinthus Biotherapeutics in the NASDAQ 100?
No, Barinthus Biotherapeutics is not included in the NASDAQ 100 index
Is Barinthus Biotherapeutics in the Dow Jones?
No, Barinthus Biotherapeutics is not included in the Dow Jones index
When was Barinthus Biotherapeutics the previous earnings report?
No data
When does Barinthus Biotherapeutics earnings report?
The next expected earnings date for Barinthus Biotherapeutics is 20 March 2025